Views & Analysis | Perspectives on pharma industry issues

Skip to main content

Sunday 12 April 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

R&D

handshake and corporate body in the background of

Changing Faces: Pharma and biotech, March 2026

A broad mix of senior leadership and scientific and commercial appointments shaped last month’s pharma and biotech hiring activity.

Market Access

General Counsel in corporate environment

For life sciences, it’s not only about when to bring on a GC...

For founders, the question is no longer just who to hire as GC, but when to hire them, and what comes next.

Patients

Female patient engages with her female doctor

Return on Engagement (ROE): A new framework to better captur...

Return on Engagement (ROE) is a call to action to better capture the multifaceted value of patient engagement.

Oncology

Interview at LSX 2026 with Roi Raz

LSX2026: Addressing adult eye cancer, with Roi Raz

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

Market Access

Young girl gives high five to her female doctor, mum also in the consult room

A step forward, but not the finish line: What NICE’s QALY up...

Healthcare in the UK is at an inflection point.

Market Access

drug discount management

A critical year for drug discount management

Two programmes created in the early 1990s with the intention of helping consumers pay for their prescribed medications are expected to expand substantially in 2024.

R&D

cell and gene therapy background

Three key decisions cell and gene therapy trial sponsors nee...

It’s no wonder the cell and gene therapy (CAGT) market is piquing interest from the broader healthcare ecosystem by offering hope to patients where traditional treatments may have fallen sh

Sales & Marketing

behavioural change

Behavioural science in biopharma: Convincing backers and phy...

Novel therapies, often with expensive price tags and finite patient populations, require strategic new positioning if they are to have maximum positive impact.

Load more results

Sales & Marketing

Sales & Marketing

Middle East from space, at night

How war in the Middle East is disrupting medical supply chai...

The impact of the geopolitical disruption is starting to tell on global supply chains for medicines and key chemicals for the pharmaceutical industry.

Sales & Marketing

Interview with Craig Ackerman Reuters at Pharma USA 2026

Biotech is back, with Craig Ackerman

In Philadelphia last month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.

Digital

Digital

Augmented intelligence concept

Augmented intelligence: The next-gen engine for biopharma in...

Augmented intelligence is strategically valuable because it strengthens both the scientific and financial case for every decision.

Digital

lady pointing at a number of data points

Sponsored

Solution Spotlight: Medscape AI

Medscape AI introduces a global, medical-grade AI search tool exclusively curated from the world’s largest body of clinically vetted content.

Market Access

Market Access

General Counsel in corporate environment

For life sciences, it’s not only about when to bring on a GC...

For founders, the question is no longer just who to hire as GC, but when to hire them, and what comes next.

Market Access

Young girl gives high five to her female doctor, mum also in the consult room

A step forward, but not the finish line: What NICE’s QALY up...

Healthcare in the UK is at an inflection point.

Editor's Picks

Gilead strikes again, penning $5bn deal to buy Tubulis

US judge blocks bid to curb abortion pill access

Kennedy changes vaccine panel charter after legal setback

Jeito closes 'record' $1.2bn Europe-focused biopharma fund

Boehringer transfers schizophrenia DTx selling rights to Click

Newsletters and Deep Dive
digital magazine

Get Newsletters

Get in-depth news, opinions, and features on pharma and healthcare sent straight to your inbox

Oncology

Oncology

Interview at LSX 2026 with Roi Raz

LSX2026: Addressing adult eye cancer, with Roi Raz

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

Oncology

Oncologists assessing a brain scan

From preclinical toxicology to clinical safety: The path for...

Successfully navigating the process for drugs with a higher risk-benefit ratio requires a tailored non-clinical programme design.

Oncology

DNA strand

Advancing the case for cell and gene therapies

After the Advanced Therapies Congress, Europe, pharmaphorum spoke with Resolution Therapeutics' Lara Campana and Vianautis' Dr Sam Barker.

Patients

Patients

Female patient engages with her female doctor

Return on Engagement (ROE): A new framework to better captur...

Return on Engagement (ROE) is a call to action to better capture the multifaceted value of patient engagement.

Patients

Brain puzzle with piece missing, letting through the sunlight

Exploring mixed episodes in bipolar I disorder: When mania a...

One of the most misunderstood and often overlooked aspects of BD-I is the occurrence of mixed episodes.

Patients

Interview with Matt Wadyka at Reuters Pharma USA 2026

Making direct-to-patient work, with Matt Wadyka

Matt Wadyka, chief client strategy officer at Inizio Medical, spoke to pharmaphorum about the ins and outs of direct-to-patient programmes in pharma.

R&D

R&D

handshake and corporate body in the background of

Changing Faces: Pharma and biotech, March 2026

A broad mix of senior leadership and scientific and commercial appointments shaped last month’s pharma and biotech hiring activity.

R&D

The Journey of a Small Molecule

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

R&D

pharmaphorum podcast Episode 253, Lance Baldo, Beacon Therapeutics

Looking to gene therapy for ocular diseases, with Lance Bald...

Lance Baldo, CEO of Beacon Therapeutics, discusses the transformative power of gene therapy to deliver meaningful outcomes for severe ocular diseases.

Editor's Picks

Gilead strikes again, penning $5bn deal to buy Tubulis

US judge blocks bid to curb abortion pill access

Kennedy changes vaccine panel charter after legal setback

Jeito closes 'record' $1.2bn Europe-focused biopharma fund

Boehringer transfers schizophrenia DTx selling rights to Click

News

Two boxes and doses of Senju

Senju launches first-in-class dry eye disease drug in Japan

Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights further

Sponsored

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company